Tilray | TRLY - Debt


Tilray reported $640.95M in Debt for its fiscal quarter ending in June of 2022.





Debt Change Date
Acasti Pharma USD 0 0 Sep/2024
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Aurora Cannabis CAD 100.34M 1.29M Sep/2025
Avita Medical AUD 46.05M 1.46M Dec/2025
Canopy Growth CAD 259.33M 68.47M Sep/2025
Cronos Group USD 1.51M 233K Dec/2025
Dianthus Therapeutics USD 1.28M 45K Sep/2025
Divis Laboratories Ltd INR 40M 40M Mar/2025
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
IQVIA Holdings USD 15.83B 109M Mar/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
Moderna USD 1.31B 571M Dec/2025
Organon & Co USD 8.64B 184M Dec/2025
Revvity USD 3.4B 29.2M Dec/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Tilray USD 640.95M 35.17M Jun/2022
Viatris USD 14.34B 69.3M Mar/2026
Xeris Pharmaceuticals USD 257.65M 431K Sep/2025